Lucira Health, Inc.: Nasdaq/NYSE listing notice — Lucira Health gets FDA EUA for first at-home COVID-19 & flu test; Nasdaq delisting set for March 6

Lucira Health, Inc.

FDA granted EUA for Lucira COVID-19 & Flu Home Test, first OTC at-home test for flu and combo COVID-19/flu.
Test is molecular (NAAT), delivers results in 30 minutes from one nasal swab; similar performance to lab PCR.
Nasdaq notified delisting due to Chapter 11 filing; trading suspended at opening on March 6, 2023; company will not appeal.
Company produced inventory for autumn 2022 launch but could not bridge authorization cycle; now seeking strategic or financial partner.
Bankruptcy court approved first-day motions on Feb 24 to continue ordinary operations during Chapter 11 case.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Lucira Health, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

Exchange: nasdaq
Notice: delisting notice
Rules: 5101, 5110(b), IM-5101-1

Exact text from the filing

February 23, 2023, the Company received written notice (the “Delisting Notice”) from the staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Filing and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 Filing and associated public interest concerns raised by it, concerns regarding the residual equity interest of the existing listed securities holders and co

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-050739

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.